DBV Technologies S.A. (EPA:DBV)
3.645
+0.085 (2.39%)
At close: Feb 20, 2026
DBV Technologies Employees
DBV Technologies had 117 employees as of September 30, 2025. The number of employees increased by 9 or 8.33% compared to the same quarter last year.
Employees
117
Change
9
Growth
8.33%
Revenue / Employee
€40,080
Profits / Employee
€911,546
Market Cap
1.08B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 117 | 9 | 8.33% | 117 | 0 |
| Jun 30, 2025 | 109 | 3 | 2.83% | 109 | 0 |
| Mar 31, 2025 | 106 | 1 | 0.95% | 106 | 0 |
| Dec 31, 2024 | 110 | 5 | 4.76% | 109 | 1 |
| Sep 30, 2024 | 108 | 11 | 11.34% | 108 | 0 |
| Jun 30, 2024 | 106 | 18 | 20.45% | 106 | 0 |
| Mar 31, 2024 | 105 | 17 | 19.32% | 105 | 0 |
| Dec 31, 2023 | 105 | 19 | 22.09% | 104 | 1 |
| Sep 30, 2023 | 97 | 12 | 14.12% | 97 | 0 |
| Jun 30, 2023 | 88 | 1 | 1.15% | 88 | 0 |
| Mar 31, 2023 | 88 | 0 | - | 88 | 0 |
| Dec 31, 2022 | 86 | -6 | -6.52% | 85 | 1 |
| Sep 30, 2022 | 85 | -7 | -7.61% | 85 | 0 |
| Jun 30, 2022 | 87 | -10 | -10.31% | 87 | 0 |
| Mar 31, 2022 | 88 | -16 | -15.38% | 88 | 0 |
| Dec 31, 2021 | 92 | -50 | -35.21% | 92 | 0 |
| Sep 30, 2021 | 92 | -219 | -70.42% | 92 | 0 |
| Jun 30, 2021 | 97 | -214 | -68.81% | 97 | 0 |
| Mar 31, 2021 | 104 | -207 | -66.56% | 104 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 700 |
| Cellectis | 222 |
| Genfit | 188 |
| Innate Pharma | 174 |
| Transgene | 147 |
| MedinCell | 145 |
| Nanobiotix | 103 |
| Inventiva | 84 |
DBV Technologies News
- 11 days ago - DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children - Nasdaq
- 11 days ago - DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - GlobeNewsWire
- 16 days ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 - GlobeNewsWire
- 5 weeks ago - DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - GlobeNewsWire
- 5 weeks ago - Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 6 weeks ago - Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 - GlobeNewsWire
- 2 months ago - The Insider Report: A Tape Fitting for the Holiday - Benzinga
- 2 months ago - DBV Launches, Up As Much As 46%, On A New Approach To Peanut Allergy - Investor's Business Daily